标题：奥美沙坦酯治疗慢性心力衰竭的疗效及其对血清 IL-23的影响

      作者：胡智华 1，方智敏 1，黄振达 1，李国锋 2
    (1.惠州市第六人民医院惠州市惠阳区人民医院内科，广东 惠州 516211；
2.东莞市人民医院心血管内科，广东 东莞 523018)

      卷次： 2014年25卷16期

      【摘要】 目的 探讨奥美沙坦酯治疗慢性心力衰竭的疗效及其对血清 IL-23的影响。方法 选取我院心内
科2012年5月至2013年5月收治的200例慢性心力衰竭患者为研究对象，应用随机数字表法将其分为对照组和
观察组各100例，对照组患者接受常规治疗，观察组患者则在上述治疗的基础上加用奥美沙坦酯，治疗10周，比
较两组患者的临床疗效、血清 IL-23、B型脑钠肽(BNP)、Ⅰ型前胶原氨基端肽(PINP)、Ⅲ型前胶原氨基端肽
(PIIINP)、左室舒张末期内径(LVEDD)和左室射血分数(LVEF)情况。结果 治疗10周后，观察组患者治疗总有效
率达98.00%，高于对照组的92.00%，差异有统计学意义(P<0.05)。观察组患者血清 IL-23、BNP、PINP、PIIINP也
明显低于对照组患者，差异均有统计学意义(P<0.05)。观察组患者的LVEDD和LVEF明显优于对照组患者，差异
也有统计学意义(P<0.05)。结论 奥美沙坦酯治疗慢性心力衰竭患者临床疗效确切，能够有效的控制血清
IL-23、BNP、PINP、PIIINP各项实验室指标，优化LVEDD和LVEF，值得临床上进一步推广应用。

      【关键词】 奥美沙坦酯；慢性心力衰竭；临床疗效

      【中图分类号】 R541.6 【文献标识码】 A 【文章编号】 1003—6350（2014）16—2354—03


Curative effect of olmesartan medoxomil on the treatment of chronic heart failure and its impact on the serum
IL-23 level.
HU Zhi-hua 1, FANG Zhi-min 1, HUANG Zhen-da 1, LI Guo-feng 2. 1. Department of Internal Medicine, the
Sixth People's Hospital in Huizhou City, the People's Hospital of Huiyang District in Huizhou City, Huizhou 516211,
Guangdong, CHINA; 2. Department of Cardiovascular Internal Medicine, the People's Hospital of Dongguan, Dongguan
523018, Guangdong, CHINA

【Abstract】 Objective To investigate the curative effect of olmesartan medoxomil on the treatment of chronic
heart failure and its impact on the serum IL-23. Methods Two hundred patients with chronic heart failure in the De-
partment of Cardiology in our hospital from May 2012 to May 2013 were selected and divided into control group and
observation group by random number table. The control group received routine treatment, while the observation group
patients were treated by olmesartan medoxomil besides the routine treatment. The clinical curative effect, serum IL-23
level, B-type brain natriuretic peptide (BNP), procollagen Ⅰ N-terminal peptide (PINP), procollagen Ⅲ N-terminal
peptide (PIIINP), left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) of the
two groups were compared after 10 weeks treatment. Results After 10 weeks treatment, the total effective rate of the
observation group was 98%, which was significantly higher than that of the control group (92%) with statistically sig-
nificant difference, P<0.05. Serum IL-23, BNP, PINP, PIIINP levels of the observation group were significantly lower
than those of the control group with statistically significant difference, P<0.05. The left ventricular end diastolic diame-
ter and left ventricular ejection fraction of the observation group were significantly better than those of the control
group, with statistically significant difference, P<0.05. Conclusion The curative effect of olmesartan medoxomil on
the treatment of chronic heart failure is distinguish, which can effectively control laboratory indexes, such as the se-
rum levels of IL-23, BNP, PINP, PIIINP, and optimize the left ventricular end diastolic diameter and left ventricular
ejection fraction. Therefore, it is worthy of further application in clinical practice.

      【Key words】 Olmesartan medoxomil; Chronic heart failure; Clinical effect
基金项目：广东省惠州市科技计划项目（编号：2013Y194）